Impact of COVID-19 Pandemic Waves on Colorectal Cancer Stage Migration and Diagnostic Delays

NCT07328399 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 198

Last updated 2026-01-09

No results posted yet for this study

Summary

Background/Objectives: The incidence of colorectal cancer in Hungary exceeds the EU (European Union) average, and the cancer mortality rate is also among the highest in the country. The COVID-19 pandemic has impacted various areas of healthcare, including cancer diagnosis and treatment. Due to the measures taken to combat the COVID-19 pandemic, not only newly suspected cancer patients but also those already diagnosed and undergoing treatment faced numerous difficulties. Methods: The study included 198 patients with colorectal cancer, of whom 43 participants were newly diagnosed cases. Due to low case numbers in certain COVID-19 waves, adjacent waves were merged for statistical analysis. The number of newly diagnosed colorectal cancer cases across COVID-19 waves was compared using one-way ANOVA, stage distribution differences and the proportion of missed treatments were assessed with Fisher's exact test. In follow-up patients, changes were analyzed using the Wilcoxon signed-rank test. Differences in tumor size categories were examined using chi-square tests.

Conditions

Sponsors & Collaborators

  • University of Pecs

    lead OTHER

Principal Investigators

  • József Tollár, Dr. · University of Pécs, Faculty of Health Sciences, Hungary

  • Adrienn Biró, Dr. · Somogy County Móricz Kaposi Teaching Hospital, 7400 Kaposvár, Hungary

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Hungary

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07328399 on ClinicalTrials.gov